Crystal-Induced Arthritis

  • Nages Nagaratnam
  • Kujan Nagaratnam
  • Gary Cheuk
Reference work entry


The incidence of gout seems to be rising in the elderly, both in men and women in countries where the life expectancy is lengthening and the frequency of overuse of diuretics. Gout predominantly affects the middle ages and elderly people and rarely occurs in young adult or children. CPPD crystal deposition disease is the second most common form of crystal-induced arthritis and is common in the elderly. The chapter discusses the pathogenesis of gout and clinical management.


Gout Crystal-induced arthritis Elderly-onset gout Hyperuricemia CPPD crystal deposition disease 


  1. 1.
    Eggebeen AT. Gout: an update. Am Fam Physician. 2007;76:801–8.PubMedGoogle Scholar
  2. 2.
    De Leonardis F, Govoni M, Colina M, Bruschi M, Trotta F, Elderly-onset gout: a review. Rheumat Int. 2007;28:1–6.CrossRefGoogle Scholar
  3. 3.
    Fam AG. Gout in the elderly: Clinical presentation and treatment. Drugs Aging. 1998;13:229–243.CrossRefPubMedGoogle Scholar
  4. 4.
    Staessen J. The determination and prognostic significance of serum uric acid in elderly patients of the European Working Party high blood pressure on the Elderly trial. Am J Med. 1999;90(3A):50S–54S.Google Scholar
  5. 5.
    Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight changes, hypertension, diuretic use and risk of gout in men: the health professional follow-up study. Arch Intern Med. 2005;165:742–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Arromdee E, Michet CJ, Growson CS, Fallon S, Gabriel SE. Epidemiology of gout: Is the incidence rising? J Reumatol. 2002;29:2403–6.Google Scholar
  7. 7.
    Mikuls TR, Farrar JT, Bilker WNB, Fernsndes S, Schumacher HR Jr, Saag KG. Gout epidemiology: Results from the United Kingdom general practice research data base. 1990–1999. Ann Rheum Dis. 2005;64:267–272.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Matsuo H, Ichida K, Takada T, Nakayama A, Nakashima H, Nakamura T, et al. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep. 2013;3:2014.
  9. 9.
    Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010; 69:1907–1912.CrossRefPubMedGoogle Scholar
  10. 10.
    Ea HK. Mechanisms of gout inflammation. PreseMed. 2011;40(9Pt1):836–43.Google Scholar
  11. 11.
    Rider TG, Jordan KM. The modern management of gout. Rheumatology (Oxford). 2010;49(1):5–14.CrossRefPubMedGoogle Scholar
  12. 12.
    Cronstein BN, Terkaltaub R. The inflammatory process of gout and its treatment. Arthritis Res. Ther. 2006;8:S1.CrossRefGoogle Scholar
  13. 13.
    Petrillie V, Martinn P. The inflammasome acute inflammatory diseases and gout. Joint Bone Spine. 2007;74:571–6.CrossRefGoogle Scholar
  14. 14.
    Martinon V, Petrilli A, Mayor A, Tardivel A, Tschopp J. Gout associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;44092081):237–241.CrossRefGoogle Scholar
  15. 15.
    Choi HK, Mpunt DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143:499–51616.CrossRefPubMedGoogle Scholar
  16. 16.
    Graessler J, Graessle A., Unger S, Kopprsch S, Tausche AK, Kuhlisch E, et al. Association of human urate transporter-1 with reduced renal uric acid excretion and hyperuraecaemia in a German Caucasian population. Arthritis Rheum. 2006;54:292–300.CrossRefPubMedGoogle Scholar
  17. 17.
    Dalbeth N, Merriman T. Crystal ball gazing: new therapeutic targets for hyperuraecaemia and got. Rheumatology. 2009;48:222–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Julkunen H, Konttinen YT. The clinical picture of gout is changing. Duodecim. 2010;126(12):1477–85.PubMedGoogle Scholar
  19. 19.
    Ter Borg EJ, Rasker JJ. Gout in the elderly: a separate entity? Ann Rheum Dis. 1987;46:72–76.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Doherty M, Dieppe P. Crystal deposition in the elderly. Clin Rheum Dis. 1986;12:97–116.PubMedGoogle Scholar
  21. 21.
    Centers for Disease Control and Prevention. Gout. retrieved 6 March 2015.
  22. 22.
    Rott KJ, Agudedo CA. Gout. JAMA. 2003;289:2857–2860.CrossRefPubMedGoogle Scholar
  23. 23.
    Yu T. Gout. In Katz WA ed. Diseases and Management of Rheumatic Diseases, ed. 2. Philadelphia. Lippincott Comp. 1988, pp 544–561.Google Scholar
  24. 24.
    Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician. 1999;59(7):1799–1806.PubMedGoogle Scholar
  25. 25.
    McQueen FM, Reeves Q, Dalbeth N. New insights in an old disease: advanced imaging in the diagnosis and management of gout. Postgrad Med J. 2013;89;87–93.CrossRefPubMedGoogle Scholar
  26. 26.
    Chowalloor PV, Siew TK, Keen HI. Imaging in gout. A review of recent developments. Ther Adv Musculoskelet Dis. 2014;8(4):136–143.Google Scholar
  27. 27.
    Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheumatology. 2007;46:1116–21.CrossRefPubMedGoogle Scholar
  28. 28.
    Lai K, Chiu Y. Role of ultrasonography in diagnosing gouty arthritis. J Med Ultrasound. 2011;19:7–13.CrossRefGoogle Scholar
  29. 29.
    McQueen FM, Doyle A, Dalbeth N. Imaging in gout-what can we learn from MRI, CT, DECT and US? Arthritis Res Ther. 2011;13:246.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Schlesinger N. Management of acute and chronic gouty arthritis: present state of the art. Drugs. 2004;64(21):2399–416.CrossRefPubMedGoogle Scholar
  31. 31.
    Cavagna L, Taylor WJ. The emerging role of biotechnological drugs in the treatment of gout. Biomed Res Int. 2014;2014:264859. Scholar
  32. 32.
    Wechalekar MD, Vinil O, Schlesnger N, Buchbinder R. Intra-articular of glucocorticoids for acute gout. Cochrane Database System, Rev 2011,
  33. 33.
    McGill N. Management of acute gout. Aust Prescr. 2004;27:10–3.CrossRefGoogle Scholar
  34. 34.
    Khanna D, Khanna PB, Fitzgerald JD, Singh MK, Sangmee BAE, Neogi T et al. American College of Rheumatology. Guidelines and management of gout. Part 2 Therapy antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10): 1447–1461.Google Scholar
  35. 35.
    Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine. 2013;80(3):291–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Morris I, Varughese G, Mattingly P. Lesson of the week-Colchicine in acute gout. BMJ. 2001;13:240–244.Google Scholar
  37. 37.
    Richette P. Gout: an overview of available urate lowering therapies. Ann Pharm Fr. 2012;70(3):33–8.CrossRefGoogle Scholar
  38. 38.
    George L, Sudy JS. Pegloticase for treating refractory chronic gout. Drugs Today (Brc). 2012;48(7):441–9.Google Scholar
  39. 39.
    Suresh E, Das P. Recent advances in management of gout. QJM. 2012;105(5):407–17.CrossRefPubMedGoogle Scholar
  40. 40.
    Globalrph Gout treatment/Elevated uric acid levels. accessed 7 March 2015.
  41. 41.
    Avena-Woods C, Hilas O. Febuxostat (Uloric). A new treatment option for gout. Journal List. PT.v35(2);2010. PMC 2827920.Google Scholar
  42. 42.
  43. 43.
  44. 44.
  45. 45.
    Steika BS, May J. New gout managing guidelines: A quick and easy guide. Medscape. accessed 4 March 2015.
  46. 46.
    Lindsay K, Gow P, Vanderpyl J, Logo P, Dalbeth N. The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol. 2011;17(1):1–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Singh JA. The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther. 2014;16:R132.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Khanna PP, Nuli G, Bardon T, Tauschi AK, Forsyth A, Goven A, et al. Tophi and frequent gout flares are associated: quality of life, productivity sand increased health care costs resource use: Results from a cross sectional survey. Health Quality Outcomes. 2012;10:117.CrossRefGoogle Scholar
  49. 49.
    Roddy Z, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case – control study. Rheumatology (Oxford). 2007;46:1441–1444.CrossRefPubMedGoogle Scholar
  50. 50.
    Shields E, Besrd SM. A systematic review of the economic and humanistic burden of gout. Pharmacoeconomics. 2015.
  51. 51.
    Smith E, Hoy D, Crooss M, Merriman TR, Vos T, Buchbinder R, Woolf A, et al. The global burden of gout: estimates from the Global Burden of Disease. 2010 study. Ann Rheum Dis. 2014;73(8):1470–6.CrossRefPubMedGoogle Scholar
  52. 52.
    McCarty DJ. Crystal induced arthritis. Dis Mon 1994;40(6):255–59.CrossRefPubMedGoogle Scholar
  53. 53.
    George RL Jr, Sundy JS. Pegloticase for treating refractory gout. Drugs Today (Barc). 2012;48(7):441–9.PubMedGoogle Scholar
  54. 54.
    Winzer M, Grassler J, Aringer M. Crystal-induced arthritis-old but important. Z Rheumatol. 2007;66:317–74.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Nages Nagaratnam
    • 1
  • Kujan Nagaratnam
    • 1
  • Gary Cheuk
    • 2
  1. 1.The University of SydneyWestmead Clinical SchoolWestmeadAustralia
  2. 2.Rehabilitation and Aged Care ServiceBlacktown-Mt Druitt HospitalMount DruittAustralia

Personalised recommendations